Svar Life Science

June 29, 2023

EDITORIAL ARTICLE: Cell-based assays in immuno-oncology: Advancing bispecific antibody development

In this Editorial Article,  Dr. Peter Wolff -Implementation Scientist, AGC Biologics -describes the potential of BsAbs as an exciting immuno-oncology therapeutic and the role of the CD3 receptor in their mode of action. 

Dr. Wolff also explores how reliable and robust cell-based assays and analytical techniques are integral in the assistance of bringing these new modality drugs to market.

June 29, 2023

EDITORIAL ARTICLE: Cell-based assays in immuno-oncology: Advancing bispecific antibody development

In this Editorial Article,  Dr. Peter Wolff -Implementation Scientist, AGC Biologics -describes the potential of BsAbs as an exciting immuno-oncology therapeutic and the role of the CD3 receptor in their mode of action. 

Dr. Wolff also explores how reliable and robust cell-based assays and analytical techniques are integral in the assistance of bringing these new modality drugs to market.

iLite® CD3 Effector Cell/T-Cell Activation Bioassays -  Optimal way of measuring the efficacy of antibodies

Many new modality drugs -like Bispecific antibodies- are often more highly targeted than traditional drugs, aiming to achieve a more precise and effective treatment while minimizing side effects.

This, of course, will require more specific assays and analytical techniques to investigate the detailed mode of action for the drug.

iLite® CD3 Effector Cell/T-Cell Activation Bioassays have been designed to offer a convenient and powerful way of measuring the efficacy antibodies have to elicit T cell activation through CD3  interactions. 


Complete the form to access the editorial article!